Kamali Chance, Head of Global Biosimilars Regulatory Strategy at Quintiles, notes that all patients, regardless of what arm of the clinical trial they are in, will receive the active product and John Doyle, Senior VP & Managing Director of Global Market Access Consulting, Quintiles, describes how patients will gain the ability to have their opinions heard on the outcomes of research.